Tibet Weixinkang Medicine(603676)

Search documents
卫信康:西藏卫信康医药股份有限公司关于使用暂时闲置募集资金进行现金管理的公告
2023-08-22 08:19
西藏卫信康医药股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 证券代码:603676 证券简称:卫信康 公告编号:2023-031 现金管理额度:最高额度不超过人民币 3,000.00 万元(含 3,000.00 万 元)。 委托理财品种:仅限于安全性高、流动性好的保本型理财产品或存款类 产品。 履行的审议程序:西藏卫信康医药股份有限公司(以下简称"公司") 于 2023 年 8 月 22 日召开第三届董事会第七次会议、第三届监事会第七次会议, 分别审议通过了《关于使用暂时闲置募集资金进行现金管理的议案》。公司独立 董事发表了同意的独立意见,该议案无需提交公司股东大会审议。 特别风险提示:尽管公司及全资子公司拟购买的理财产品或存款类产品 为安全性高、流动性好的保本型产品,但仍不排除因市场波动、宏观经济及金融 政策变化、操作风险等原因引起的影响收益的情况。 一、 委托理财概况 (一) 委托理财目的 为提高募集资金使用效率,合理利用闲置募集资金,在不影响募集资金投资 项目建设和保证资金安全性的情况下,公司及全资子公司拟对部分闲置募集资金 进行现金管理,以期增加资金收益,更好的实现公司资金的保值增值,保障 ...
卫信康:西藏卫信康医药股份有限公司2023年半年度募集资金存放与实际使用情况的专项报告
2023-08-22 08:19
经中国证券监督管理委员会《关于核准西藏卫信康医药股份有限公司首次公开发行股票的 批复》(证监许可〔2017〕1098 号)核准,西藏卫信康医药股份有限公司(以下简称"公司") 公开发行人民币普通股(A 股)6,300 万股,每股面值人民币 1 元,每股发行价格为人民币 5.53 元,募集资金为人民币 348,390,000.00 元,扣除与发行有关的费用(不含税)人民币 51,354,558.49 元后,募集资金净额为 297,035,441.51 元,款项已由主承销商中信证券股份 有限公司(以下简称"中信证券")于 2017 年 7 月 17 日汇入公司募集资金监管账户。上述募 集资金到位情况经瑞华会计师事务所(特殊普通合伙)验证,并由其出具瑞华验字第 [2017]01300022 号《验资报告》。 (二) 募集资金以前年度使用金额 证券代码:603676 证券简称:卫信康 公告编号:2023-030 西藏卫信康医药股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律 ...
卫信康:西藏卫信康医药股份有限公司关于收到政府补助的公告
2023-08-14 08:41
证券代码:603676 证券简称:卫信康 公告编号:2023-027 西藏卫信康医药股份有限公司 关于收到政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 获得补助金额:2023 年 1 月 18 日至 2023 年 8 月 14 日,西藏卫信康医 药股份有限公司(以下简称"公司")及全资子公司累计收到与收益相关的政府 补助共计 4,298.54 万元。 当期损益的影响:公司及全资子公司本次累计获得的与收益相关的政府 补助 4,298.54 万元,其中 4,117.89 万元计入营业外收入,180.65 万元计入其 他收益,将对公司 2023 年度的净利润产生一定影响。鉴于公司 2023 年数据未经 审计,具体的会计处理及其对公司相关财务数据的影响将以会计师事务所年度审 计确认后的结果为准。 一、 获得补助的基本情况 (一) 获得补助概况 自 2023 年 1 月 18 日至 2023 年 8 月 14 日,公司及全资子公司累计收到与 收益相关的政府补助 4,298.54 万元(未经审计),占公司 ...
卫信康:西藏卫信康医药股份有限公司关于变更持续督导保荐代表人的公告
2023-08-08 08:41
证券代码:603676 证券简称:卫信康 公告编号:2023-026 西藏卫信康医药股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 西藏卫信康医药股份有限公司(以下简称"公司")于近日收到中信证券股份有限 公司(以下简称"中信证券")出具的《关于更换保荐代表人的函》,中信证券作为公司 2017年首次公开发行A股股票项目的保荐机构,持续督导期至2019年12月31日止,公司 首次公开发行A股股票的持续督导期已届满。鉴于本次发行股票的募集资金尚未使用完 毕,中信证券仍对募集资金使用情况继续履行持续督导责任。原委派持续督导保荐代表 人罗耸先生因工作变动原因,不再负责公司持续督导工作,为保证持续督导工作的有序 进行,中信证券已授权保荐代表人王琦先生(简历附后)接替罗耸先生担任公司持续督 导期间的保荐代表人,继续履行持续督导职责。 本次变更不影响中信证券对公司的持续督导工作。本次保荐代表人变更后,公司首 次公开发行股票的持续督导保荐代表人为王栋先生和王琦先生。 公司董事会对罗耸先生在持续督 ...
卫信康(603676) - 2022 Q4 - 年度财报
2023-04-25 16:00
Financial Performance - The company's operating revenue for 2022 was CNY 1,398,543,027.72, representing a year-on-year increase of 35.31% compared to CNY 1,033,622,524.77 in 2021[22]. - The net profit attributable to shareholders of the listed company reached CNY 176,958,679.06, an increase of 84.50% from CNY 95,911,098.26 in the previous year[22]. - The net cash flow from operating activities was CNY 246,153,584.39, reflecting a 44.21% increase compared to CNY 170,688,769.46 in 2021[23]. - The total assets of the company at the end of 2022 were CNY 1,664,718,174.54, which is an 11.31% increase from CNY 1,495,569,265.97 at the end of 2021[23]. - The net assets attributable to shareholders of the listed company increased to CNY 1,220,585,454.95, a growth of 14.37% from CNY 1,067,264,112.89 in the previous year[23]. - The company's operating revenue for 2022 reached RMB 1.399 billion, representing a year-on-year increase of 35.31%[32]. - Net profit attributable to shareholders increased by 84.50% year-on-year, amounting to RMB 177 million, while the net profit excluding non-recurring gains and losses rose by 90.95% to RMB 155 million[25][32]. - Basic and diluted earnings per share increased by 78.26% to RMB 0.41, and the basic earnings per share after excluding non-recurring gains and losses rose by 89.47% to RMB 0.36[24][25]. - The weighted average return on equity increased by 6.11 percentage points to 15.55%[24]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 2.35 per 10 shares to all shareholders, pending approval at the shareholders' meeting[5]. - The company declared a cash dividend of CNY 102,262,952.50, which represents 57.79% of the net profit attributable to ordinary shareholders in the consolidated financial statements[158]. - The cash dividend per 10 shares is CNY 2.35, with no stock bonus or capital increase from capital reserves[158]. - The company distributed cash dividends of 1.6 yuan per 10 shares, totaling 69,747,040 yuan (including tax) based on a total share capital of 435,919,000 shares[155]. Market and Sales Performance - The sales revenue of the multi-vitamin injection product reached RMB 182 million, a significant increase of 232.17%[33]. - The market terminal sales of trace element injection reached 866 million CNY, a year-on-year increase of 14.62%, with a market share of 15.48% in public medical institutions[34]. - The pediatric multivitamin injection achieved sales revenue of 45 million CNY in 2022, representing a year-on-year growth of 52.97%[34]. - The company has completed bidding and listing in 30 provincial administrative regions for its multi-vitamin injection, maintaining over 80% market share in similar products[33]. - The company has strengthened its sales channel construction and academic promotion efforts to support sales growth[33]. - The self-produced sales model generated ¥406,404,654.86 in revenue, with a gross margin of 91.29%[70]. - The cooperative sales model contributed ¥991,909,015.06, with a gross margin of 36.77%[70]. Research and Development - The company has over 30 ongoing research projects, with three products expected to receive approval in 2023[36]. - The company is actively enhancing its R&D capabilities, focusing on high-difficulty and high-barrier products, and has initiated the construction of a new laboratory in Nanjing[35]. - The company has received acceptance for the registration applications of five products, including dopamine hydrochloride injection and various trace element injections[36]. - The company emphasizes quality management and lean production principles, ensuring strict control over all stages from R&D to logistics[37]. - The company is committed to R&D innovation, continuously developing new products with independent intellectual property rights in the fields of vitamins and trace elements[46]. - The company has developed over 30 new product projects, with 14 invention patents and 17 new drug certificates obtained since 2015[62]. - Research and development expenses increased by 90.57% to 72.45 million RMB, indicating a strong focus on innovation[67]. - The company's R&D investment accounted for 5.71% of its operating revenue and 6.55% of its net assets during the reporting period[101]. - The company’s R&D investment is crucial for maintaining its innovative product pipeline and market competitiveness[96]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors with expertise in accounting, law, and pharmaceuticals, ensuring compliance with legal requirements[126]. - The company has established a modern corporate governance structure that promotes effective operation and protects the interests of all shareholders[125]. - The company maintains a transparent information disclosure system, ensuring all shareholders have equal access to information[128]. - The company has implemented a performance evaluation and incentive mechanism to motivate senior management and employees based on annual performance assessments[127]. - The company has established a compensation and assessment committee to ensure competitive and balanced remuneration[138]. Environmental Responsibility - The company has not experienced any environmental pollution incidents during the reporting period and has not faced any administrative penalties related to environmental protection[180]. - The company has implemented a detailed environmental management system and performance assessment criteria, integrating environmental management into daily operations[180]. - The company has committed to reducing carbon emissions but did not disclose specific measures or results during the reporting period[181]. - The company has focused on optimizing production processes and enhancing material recycling to minimize waste and emissions[180]. - The company has conducted regular fire safety inspections to eliminate fire hazards and ensure the normal operation of fire safety facilities[180]. Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[7]. - The company acknowledges potential risks from policy changes in the pharmaceutical industry, which may impact operational models and strategies[120]. - The company faces market risks related to drug price adjustments due to regulatory controls, which may negatively impact profitability over the long term[122]. - The company has a significant number of products in development, with a focus on establishing effective risk assessment and prevention mechanisms in its R&D processes[123]. Strategic Initiatives - The company is committed to innovation-driven strategies, optimizing product layout and structure, and enhancing R&D talent retention[35]. - The company is actively seeking international market opportunities for its core products to drive growth[118]. - The company plans to expand its research and development capabilities with the construction of the Jiangsu Zhongwei Kang R&D Center[86]. - The company plans to continue its market expansion and product development strategies in the upcoming fiscal year[133].
卫信康(603676) - 2023 Q1 - 季度财报
2023-04-25 16:00
2023 年第一季度报告 证券代码:603676 证券简称:卫信康 西藏卫信康医药股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存 在虚假记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位:元 币种:人民币 | 项目 | 本报告期 | 本报告期比上年同期增减变 | | | | --- | --- | --- | --- | --- | | | | 动幅度(%) | | | | 营业收入 | 350,378,358.40 | | | 11.13 | | 归属于上市公司股东的净利润 | 60,246,349.21 | | | 54.82 | | 归属于上市公司股东的扣除非经常 | 58,5 ...
卫信康:西藏卫信康医药股份有限公司关于召开2022年度暨2023年第一季度业绩说明会的公告
2023-04-25 10:11
会议召开地点:上海证券交易所上证路演中心(网址:http://roadsho w.sseinfo.com/) 会议召开方式:上证路演中心视频直播和网络互动 投资者可于 2023 年 5 月 4 日(星期四) 至 5 月 10 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过西藏卫信康医药股份有 限公司(以下简称"公司")邮箱 wxk@wxkpharma.com 进行提问。公司将在信息 披露允许的范围内,在说明会上对投资者普遍关注的问题进行回答。 公司已于 2023 年 4 月 26 日发布公司 2022 年年度报告、2023 年第一季度报 告,为便于广大投资者更全面深入地了解公司 2022 年度、2023 年第一季度经营 成果、财务状况,公司计划于 2023 年 5 月 11 日 15:00-16:00 举行 2022 年度暨 2023 年第一季度业绩说明会,就投资者关心的问题进行交流。 证券代码:603676 证券简称:卫信康 公告编号:2023-020 西藏卫信康医药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证 ...
卫信康(603676) - 卫信康投资者关系活动记录表(2022-05-13)
2022-11-19 03:16
证券代码:603676 证券简称:卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|---------------------------------------|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | 编号: 2022-011 | | | | | | | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | ■路演活动 | | | | □现场参观 | | | | | ■其他:电话会议 | | | | 参与单位名称及 人员 ...
卫信康(603676) - 投资者关系活动记录表(2022-05-09)
2022-11-19 03:12
证券代码:603676 证券简称:卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|-----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------| | | | | 编号: 2022-010 | | | | | | | | □特定对象调研 □分析师会议 | | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | ■其他:电话会议 | ...
卫信康(603676) - 投资者关系活动记录表(2022-05-20)
2022-11-19 01:38
证券代码:603676 证券简称:卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 编号:2022-012 | --- | --- | --- | --- | --- | |----------------|----------------------------------------------------------|----------------------------------|-------|--------------------| | | | | | | | | □特定对象调研 | □分析师会议 | | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | | 类别 | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | ■其他:电话会议 | | | | | 参与单位名称及 | 东吴证券、太平资管 | | | | | 人员姓名 | 华西证券、农银汇理基金 2022 年 05 月 17 日, | 15:00-16:00 | | | | 时间 | 年 月 日, | | | | | 地点 | 2022 05 18 | 10:00-11:1 ...